Literature DB >> 34424445

ARID1A regulates E-cadherin expression in colorectal cancer cells: a promising candidate therapeutic target.

Mehran Erfani1,2, Mozhdeh Zamani3, Seyed Younes Hosseini4, Zohreh Mostafavi-Pour1, Sayed Mohammad Shafiee1, Mohammadreza Saeidnia5, Pooneh Mokarram6,7.   

Abstract

BACKGROUND: Metastasis is a major cause of death in Colorectal cancer (CRC) patients, and the Epithelial-mesenchymal transition (EMT) has been known to be a crucial event in cancer metastasis. Downregulated expression of AT-rich interaction domain-containing protein 1A (ARID1A), a bona fide tumor suppressor gene, plays an important role in promoting EMT and CRC metastasis, but the underlying molecular mechanisms remain poorly understood. Here, we evaluated the impact of ARID1A knockdown and overexpression on the expression of EMT‑related genes, E-cadherin and β-catenin, in human CRC cells. METHODS AND
RESULTS: The expression levels of ARID1A, E-cadherin and β-catenin in CRC cell lines were detected via real-time quantitative PCR (qPCR) and western blot. ARID1A overexpression and shRNA-mediated knockdown were performed to indicate the effect of ARID1A expression on E-cadherin and β-catenin expression in CRC cell lines. The effect of ARID1A knockdown on the migration ability of HCT116 cells was assessed using wound-healing assay. We found that the mRNA and protein expression of adhesive protein E-cadherin was remarkably downregulated in response to shRNA-mediated ARID1A knockdown in HCT116 and HT29 cells. Conversely, overexpression of ARID1A in SW48 cells significantly increased E-cadherin expression. In addition, ARID1A silencing promoted the migration of HCT116 cells. ARID1A knockdown and overexpression did not alter the level of β-catenin expression.
CONCLUSIONS: Our study demonstrates that E-cadherin levels were closely correlated with ARID1A expression. Thus, ARID1A downregulation may promote CRC metastasis through decreasing EMT‑related protein E-cadherin and promoting epithelial cell movement. ARID1A could represent a promising candidate therapeutic target for CRC.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  ARID1A; Colorectal cancer; E-cadherin; β-catenin

Mesh:

Substances:

Year:  2021        PMID: 34424445     DOI: 10.1007/s11033-021-06671-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  2 in total

1.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

2.  Role of ARID1A in epithelial‑mesenchymal transition in breast cancer and its effect on cell sensitivity to 5‑FU.

Authors:  Tangshun Wang; Xiang Gao; Kexin Zhou; Tao Jiang; Shuang Gao; Pengzhou Liu; Ximeng Zuo; Xiaoguang Shi
Journal:  Int J Mol Med       Date:  2020-09-15       Impact factor: 4.101

  2 in total
  2 in total

1.  Evidence of histone modification affecting ARID1A expression in colorectal cancer cell lines.

Authors:  Mehran Erfani; Mozhdeh Zamani; Pooneh Mokarram
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

2.  Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses.

Authors:  Fangjie Hu; Jianyi Wang; Minghui Zhang; Shuoshuo Wang; Lingyu Zhao; Hao Yang; Jinrong Wu; Binbin Cui
Journal:  Front Cell Dev Biol       Date:  2021-11-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.